ICMJE DISCLOSURE FORM

Date: December 21, 2021

Your Name: Seyer Safi, M.D.

Manuscript Title: Therapy option for early-stage lung cancer in nonsurgical patients

Manuscript number (if known): https://tlcr.amegroups.com/article/view/55836

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **None**                                                                         |
|   | **Time frame:** Since the initial planning of the work |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **Else Kröner Fresenius Stiftung** Clinical trial, RadImmune trial |
| 3 | Royalties or licenses | **None**                                                                         |
| 4 | Consulting fees |                                                                                  |
|   | Question                                                                 | Response |
|---|--------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,     | Coliquio |
|   | manuscript writing or educational events                                 | Lecture  |
| 6 | Payment for expert testimony                                            | None     |
| 7 | Support for attending meetings and/or travel                            | None     |
| 8 | Patents planned, issued or pending                                      | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board        | None     |
| 10| Leadership or fiduciary role in other board, society, committee or      | None     |
|   | advocacy group, paid or unpaid                                          |          |
| 11| Stock or stock options                                                  | None     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other  | None     |
|   | services                                                                 |          |
| 13| Other financial or non-financial interests                              | None     |

Please summarize the above conflict of interest in the following box:

I received lecture payment from the above-mentioned companies. All payments were approved by the Klinikum rechts der Isar, Technical University of Munich. The author declare that there is no conflict of interest regarding the manuscript.

Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this
form.
**ICMJE DISCLOSURE FORM**

**Date:** December 21, 2021

**Your Name:** Gregor S. Zimmermann, M.D.

**Manuscript Title:** Therapy option for early-stage lung cancer in nonsurgical patients

**Manuscript number (if known):** https://tlcr.amegroups.com/article/view/55836

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **Time frame: Since the initial planning of the work** |
|   | No time limit for this item. | ____None |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **Time frame: past 36 months** |
|   | ____AstraZeneca Clinical trial, PONENTE trial | |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | |
|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Roche | Lecture |
|---|-------------------------------------------------|-------|---------|
|   |                                                 | AstraZeneca | Lecture |
|   |                                                 | GSK, Pfizer, Boehringer Ingelheim, Novartis | Lecture |
| 6 | Payment for expert testimony                     | None   |         |
| 7 | Support for attending meetings and/or travel     | None   |         |
| 8 | Patents planned, issued or pending               | None   |         |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |         |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |         |
|11 | Stock or stock options                           | None   |         |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |         |
|13 | Other financial or non-financial interests       | None   |         |

Please summarize the above conflict of interest in the following box:

I received lecture payment from the above-mentioned companies. All payments were approved by the Klinikum rechts der Isar, Technical University of Munich. The author declare that there is no conflict of interest regarding the manuscript.

Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
